Professor Graeme Hankey AO is an internationally distinguished neurologist, stroke physician and clinical trialist whose research has advanced the evidence base for acute stroke treatment and stroke prevention. He holds the Chair in Stroke Research at The University of Western Australia and Perron Institute, where he jointly leads an integrated program spanning stroke epidemiology, prevention, acute care and recovery.

Professor Hankey has led major international clinical trials such as VITATOPS and AFFINITY, and currently jointly leads the LIBREXIA-Stroke phase 3 trial of milvexian for secondary stroke prevention and the ASPIRING trial of antiplatelet monotherapy following intracerebral haemorrhage. He also provides independent scientific and safety oversight for international clinical trials and contributes to major global initiatives addressing stroke prevention, implementation and disease burden.

Together with collaborators, Professor Hankey has secured more than $80 million in competitive research funding and has been awarded a NHMRC Investigator Grant, Leadership level 3, for 2026-2030 to lead clinical trials addressing top priorities for stroke research.

He has authored or co-authored more than 1,135 publications, including 13 books and 13 clinical guidelines. His work has received more than 463,000 citations.

His international standing is further reflected in senior editorial roles with Circulation, The Lancet Neurology, Stroke and Cerebrovascular Diseases. Professor Hankey received the American Stroke Association’s David G. Sherman Award for outstanding lifetime contributions to stroke in 2015 and was appointed an Officer of the Order of Australia in 2025.

View Publications    Email